Eosinophilic Esophagitis

11
Pipeline Programs
7
Companies
6
Clinical Trials
2 recruiting
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
5
0
3
3
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
6100%
+ 4 programs with unclassified modality

On Market (2)

Approved therapies currently available

Teva
CINQAIRApproved
reslizumab
Teva
Interleukin-5 Antagonist [EPC]injection2016
Regeneron
DUPIXENTApproved
dupilumab
Regeneron
Interleukin-4 Receptor alpha Antagonist [EPC]injection2017

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Regeneron
RegeneronTARRYTOWN, NY
4 programs
1
1
1
Eosinophilic EsophagitisPhase 4
DupilumabPhase 3Monoclonal Antibody
DupilumabPhase 2Monoclonal Antibody
DupilumabN/AMonoclonal Antibody
Teva
TevaIsrael - Petach Tikva
1 program
1
1
reslizumabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT00635089Completed190Est. Jan 2012
Sanofi
SanofiPARIS, France
1 program
1
DupilumabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT03633617Completed321Est. Jun 2022
CSL Behring
CSL BehringIL - Bradley
1 program
1
Alpha-proteinase inhibitorPhase 21 trial
Active Trials
NCT05485155Recruiting15Est. Jan 2027
Revolo Biotherapeutics
1 program
1
IRL201104Phase 21 trial
Active Trials
NCT05084963Completed36Est. Oct 2022
Phathom Pharmaceuticals
Phathom PharmaceuticalsFLORHAM PARK, NJ
1 program
1
VonoprazanPhase 21 trial
Active Trials
NCT06851559RecruitingEst. Mar 2027
Celldex Therapeutics
1 program
1
barzolvolimabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT05774184Completed86Est. Jan 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
SanofiDupilumab
Tevareslizumab
Phathom PharmaceuticalsVonoprazan
CSL BehringAlpha-proteinase inhibitor
Celldex Therapeuticsbarzolvolimab
Revolo BiotherapeuticsIRL201104

Clinical Trials (6)

Total enrollment: 648 patients across 6 trials

NCT03633617SanofiDupilumab

Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)

Start: Sep 2018Est. completion: Jun 2022321 patients
Phase 3Completed
NCT00635089Tevareslizumab

Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis

Start: Jul 2008Est. completion: Jan 2012190 patients
Phase 3Completed
NCT06851559Phathom PharmaceuticalsVonoprazan

A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks

Start: Oct 2025Est. completion: Mar 2027
Phase 2Recruiting
NCT05485155CSL BehringAlpha-proteinase inhibitor

Zemaira Eosinophilic Esophagitis Pilot Study

Start: May 2025Est. completion: Jan 202715 patients
Phase 2Recruiting
NCT05774184Celldex Therapeuticsbarzolvolimab

A Study of CDX-0159 in Patients With Eosinophilic Esophagitis

Start: Jun 2023Est. completion: Jan 202686 patients
Phase 2Completed
NCT05084963Revolo BiotherapeuticsIRL201104

A Study to Assess the Efficacy, Safety and Tolerability of IRL201104 in Adults With Active Eosinophilic Esophagitis

Start: Oct 2021Est. completion: Oct 202236 patients
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 648 patients
Monoclonal Antibody is the dominant modality (100% of programs)
7 companies competing in this space